VistaGen Therapeutics(VTGN) - 2025 Q4 - Annual Results

Exhibit 99.1 Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update PALISADE-4 Phase 3 Trial topline results expected in the first half of 2026 Topline results of PALISADE-3 Phase 3 Trial of fasedienol for acute treatment of social anxiety disorder expected in the fourth quarter of this year Company showcases promising clinical-stage pipeline of five novel intranasal pherine candidates targeting six highly prevalent and underserved disorders SOUTH SAN FRANCISCO, Calif. — (BUSINESS ...